Recursion Pharmaceuticals (RXRX) experienced a price increase of 9% over the past month, positioning it against the backdrop of a broader market decline driven by geopolitical tensions and weak jobs ...

Given that, it's hardly encouraging that Biodexa has taken a big step forward ahead of Recursion in the development of its ...